Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Structural Model of the Anaphase Promoting Complex Co-Activator (Cdh1) and in Silico Design of Inhibitory Compounds



Rahimi H1 ; Negahdari B2 ; Shokrgozar MA3 ; Sobhani AM4, 5 ; Mahdian R1 ; Foroumadi A6 ; Amin MK7 ; Karimipoor M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
  2. 2. Department of Medical Biotechnology, Advanced Medical Science School, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran
  4. 4. Life Sciences Department, Barcelona Supercomputing Center (BSC), Barcelona, 08034, Spain
  5. 5. Department of Bioinformatics, Institute of Biophysics and Biochemistry (IBB), University of Tehran, Tehran, Iran
  6. 6. Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Faculty of Paramedical Sciences, Qazvin University of Medical Sciences, Qazvin, Iran

Source: Research in Pharmaceutical Sciences Published:2015

Abstract

Anaphase promoting complex (APC) controls cell cycle and chromosome segregation. The APC activation occurs after binding of co-activators, cdh1 and cdc20. Cdh1 plays a role in cancer pathogenesis and is known as a potential drug target. The main aim of this study was prediction of 3D structure of cdh1 and designing the inhibitory compounds based on the structural model. First, 3D structure of cdh1 was predicted by means of homology modelling and molecular dynamics tools, MODELLER and Gromacs package, respectively. Then, inhibitory compounds were designed using virtual screening and molecular docking by means AutoDock package. The overall structure of cdh1 is propeller like and each DW40 repeat contains four antiparallel beta-sheets. Moreover, binding pocket of the inhibitory compounds was determined. The results might be helpful in finding a suitable cdh1 inhibitor for the treatment of cancer.
4. New Engineered Fusion Peptide With Dual Functionality: Antibacterial and Strong Binding to Hydroxyapatite, International Journal of Peptide Research and Therapeutics (2020)
Experts (# of related papers)
Other Related Docs
45. Structure-Based Virtual Screening for Defeating Drug Resistant Form of Egfr Protein, Combinatorial Chemistry and High Throughput Screening (2016)